Literature DB >> 22056657

Biomarker use in colorectal cancer therapy.

Robin K Kelley1, Grace Wang, Alan P Venook.   

Abstract

Biomarkers reflective of the molecular and genetic heterogeneity in colorectal cancers now guide certain aspects of clinical management and offer great potential for enrichment, stratification, and identification of novel therapeutic targets in drug development. Using case-based examples, this article reviews biomarkers that have an established role in the clinical management of colorectal cancer: mismatch repair protein testing and KRAS and BRAF mutational analysis. A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22056657      PMCID： PMC3696980          DOI： 10.6004/jnccn.2011.0105

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  61 in total

1.  Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.

Authors:  J Randolph Hecht; Edith Mitchell; Marcus A Neubauer; Howard A Burris; Paul Swanson; Timothy Lopez; Glenn Buchanan; Maureen Reiner; Jennifer Gansert; Jordan Berlin
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

Review 2.  Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.

Authors:  Kathryn A Phillips; Stephanie L Van Bebber
Journal:  Med Care Res Rev       Date:  2006-06       Impact factor: 3.929

3.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

Review 4.  ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.

Authors:  Ming Yin; Jingrong Yan; Eva Martinez-Balibrea; Francesco Graziano; Heinz-Josef Lenz; Hyo-Jin Kim; Jacques Robert; Seock-Ah Im; Wei-Shu Wang; Marie-Christine Etienne-Grimaldi; Qingyi Wei
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

5.  Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

Authors:  Monica M Bertagnolli; Mark Redston; Carolyn C Compton; Donna Niedzwiecki; Robert J Mayer; Richard M Goldberg; Thomas A Colacchio; Leonard B Saltz; Robert S Warren
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

6.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas.

Authors:  J M Cunningham; C Y Kim; E R Christensen; D J Tester; Y Parc; L J Burgart; K C Halling; S K McDonnell; D J Schaid; C Walsh Vockley; V Kubly; H Nelson; V V Michels; S N Thibodeau
Journal:  Am J Hum Genet       Date:  2001-08-24       Impact factor: 11.025

Review 7.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Authors:  Gaëtan Des Guetz; Olivier Schischmanoff; Patrick Nicolas; Gérard-Yves Perret; Jean-François Morere; Bernard Uzzan
Journal:  Eur J Cancer       Date:  2009-05-06       Impact factor: 9.162

8.  Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

Authors:  Michael S Braun; Susan D Richman; Philip Quirke; Catherine Daly; Julian W Adlard; Faye Elliott; Jennifer H Barrett; Peter Selby; Angela M Meade; Richard J Stephens; Mahesh K B Parmar; Matthew T Seymour
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

9.  Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival.

Authors:  Sanjay Kakar; Saime Aksoy; Lawrence J Burgart; Thomas C Smyrk
Journal:  Mod Pathol       Date:  2004-06       Impact factor: 7.842

10.  mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer.

Authors:  Giovanni Lanza; Manuela Ferracin; Roberta Gafà; Angelo Veronese; Riccardo Spizzo; Flavia Pichiorri; Chang-gong Liu; George A Calin; Carlo M Croce; Massimo Negrini
Journal:  Mol Cancer       Date:  2007-08-23       Impact factor: 27.401
View more
  15 in total

1.  Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science.

Authors:  Shuji Ogino; Emily E King; Andrew H Beck; Mark E Sherman; Danny A Milner; Edward Giovannucci
Journal:  Am J Epidemiol       Date:  2012-08-30       Impact factor: 4.897

2.  Ogino et Al. Respond to "the 21st century epidemiologist".

Authors:  Shuji Ogino; Andrew H Beck; Emily E King; Mark E Sherman; Danny A Milner; Edward Giovannucci
Journal:  Am J Epidemiol       Date:  2012-08-30       Impact factor: 4.897

3.  Downregulation of a long noncoding RNA-ncRuPAR contributes to tumor inhibition in colorectal cancer.

Authors:  Bing Yan; Wei Gu; Zhihui Yang; Zhan Gu; Xiaoqiang Yue; Qunhao Gu; Long Liu
Journal:  Tumour Biol       Date:  2014-08-14

4.  Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers.

Authors:  Daiwei Wan; Songbing He; Binhui Xie; Guohui Xu; Wen Gu; Chenglong Shen; You Hu; Xinsheng Wang; Qiaoming Zhi; Liang Wang
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

Review 5.  Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.

Authors:  S Ogino; P Lochhead; E Giovannucci; J A Meyerhardt; C S Fuchs; A T Chan
Journal:  Oncogene       Date:  2013-06-24       Impact factor: 9.867

Review 6.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.

Authors:  Shuji Ogino; Charles S Fuchs; Edward Giovannucci
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

7.  Imaging a functional tumorigenic biomarker in the transformed epithelium.

Authors:  Aaron M LeBeau; Minhee Lee; Stephanie T Murphy; Byron C Hann; Robert S Warren; Romelyn Delos Santos; John Kurhanewicz; Samir M Hanash; Henry F VanBrocklin; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

8.  Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status.

Authors:  Teppei Morikawa; Aya Kuchiba; Paul Lochhead; Reiko Nishihara; Mai Yamauchi; Yu Imamura; Xiaoyun Liao; Zhi Rong Qian; Kimmie Ng; Andrew T Chan; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Res       Date:  2013-02-26       Impact factor: 12.701

9.  Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.

Authors:  Paul Lochhead; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Mai Yamauchi; Reiko Nishihara; Zhi Rong Qian; Teppei Morikawa; Jeanne Shen; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  J Natl Cancer Inst       Date:  2013-07-22       Impact factor: 13.506

Review 10.  Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.

Authors:  Shuji Ogino; Paul Lochhead; Andrew T Chan; Reiko Nishihara; Eunyoung Cho; Brian M Wolpin; Jeffrey A Meyerhardt; Alexander Meissner; Eva S Schernhammer; Charles S Fuchs; Edward Giovannucci
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.